Search for other papers by Orwa Dandash in
Google Scholar
PubMed
Search for other papers by James Allebone in
Google Scholar
PubMed
Search for other papers by Adam Mirabelli in
Google Scholar
PubMed
Search for other papers by Nicholas Russell in
Google Scholar
PubMed
Search for other papers by Mathis Grossmann in
Google Scholar
PubMed
Department of Florey Institute, University of Melbourne, Parkville, Victoria, Australia
Search for other papers by Andrea Gogos in
Google Scholar
PubMed
Search for other papers by Richard A Kanaan in
Google Scholar
PubMed
mL (0.9 mg) per day for 6 months and (ii) matching placebo group that received placebo gel 1 mL per day. Randomization occurred by stratifying participants by ADT duration (≤3 or >3 months) and then by eligibility to undergo brain MRI scanning
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Karhapää in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Siru Mäkelä in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Laurén in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Marjut Jaakkola in
Google Scholar
PubMed
Endocrinology, Abdominal Centre, University of Helsinki and HUS, Helsinki, Finland
Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Micaela Hernberg in
Google Scholar
PubMed
University Hospital with in-house methods. A whole-body CT and a brain MRI or a brain CT were performed prior to treatment initiation as well. Before each treatment cycle, we measured WBC, CRP, sodium, potassium, calcium, creatinine, ALT, ALP, bilirubin
Search for other papers by Carole Morin in
Google Scholar
PubMed
Search for other papers by Keo-Morakort Benedetto in
Google Scholar
PubMed
Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052 CNRS 5286, Lyon Cedex 08, France
Search for other papers by Agathe Deville in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, France
Search for other papers by Laurent Milot in
Google Scholar
PubMed
Search for other papers by Aurélie Theillaumas in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, France
Hospices Civils de Lyon, Institut de Pathologie Est, Bron Cedex, France
Search for other papers by Valérie Hervieu in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Gastroentérologie, Lyon Cedex 03, France
Search for other papers by Mathieu Pioche in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, France
Hospices Civils de Lyon, Hôpital Edouard Herriot, Chirurgie Digestive, Lyon Cedex 03, France
Search for other papers by Gilles Poncet in
Google Scholar
PubMed
Search for other papers by Julien Forestier in
Google Scholar
PubMed
Search for other papers by Laurent François in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Louis Pradel, Endocrinologie, Bron Cedex, France
Search for other papers by Francoise Borson-Chazot in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Chirurgie Digestive, Lyon Cedex 03, France
Search for other papers by Mustapha Adham in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052 CNRS 5286, Lyon Cedex 08, France
University of Lyon, Université Lyon 1, France
Search for other papers by Thomas Walter in
Google Scholar
PubMed
-up and the initial treatments was defined according to ENETS guidelines (French guidelines are similar) ( 3 , 6 ). Minimal work-up included laboratory test (chromogranin A), endoscopy along with endoscopic ultrasound (EUS), imaging (CT scan, MRI, and
Search for other papers by Jiaxin Luo in
Google Scholar
PubMed
Search for other papers by Weili Yin in
Google Scholar
PubMed
Search for other papers by Qiuxia Lin in
Google Scholar
PubMed
Search for other papers by Juqing Wu in
Google Scholar
PubMed
Search for other papers by Pan Chen in
Google Scholar
PubMed
Search for other papers by Yuanna Ling in
Google Scholar
PubMed
Search for other papers by Jing Wang in
Google Scholar
PubMed
Search for other papers by Zhen Li in
Google Scholar
PubMed
Search for other papers by Liqin Pan in
Google Scholar
PubMed
Search for other papers by Yanying Chen in
Google Scholar
PubMed
Search for other papers by Wei Ouyang in
Google Scholar
PubMed
Search for other papers by Huijuan Feng in
Google Scholar
PubMed
RAIT and the collecting conditions of the post-therapy whole-body scans ( 16 ). Additional SPECT/CT images were performed immediately for suspected bone metastases with I-131 uptake, and CT or MRI examinations were performed within 1 month after RAIT to
Search for other papers by Matteo Scopel in
Google Scholar
PubMed
Search for other papers by Eugenio De Carlo in
Google Scholar
PubMed
Search for other papers by Francesca Bergamo in
Google Scholar
PubMed
Search for other papers by Sabina Murgioni in
Google Scholar
PubMed
Search for other papers by Riccardo Carandina in
Google Scholar
PubMed
Search for other papers by Anna Rita Cervino in
Google Scholar
PubMed
Search for other papers by Marta Burei in
Google Scholar
PubMed
Search for other papers by Federica Vianello in
Google Scholar
PubMed
Search for other papers by Vittorina Zagonel in
Google Scholar
PubMed
Search for other papers by Matteo Fassan in
Google Scholar
PubMed
Search for other papers by Roberto Vettor in
Google Scholar
PubMed
medicine reports were mainly taken into consideration. All patients underwent total-body PET/CT imaging with 68 Ga-SSA, MRI and fluorodeoxyglucose-PET/CT focused on bone lesions. Patients who presented reports of ambiguous interpretation were discarded due
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by Mark J C van Treijen in
Google Scholar
PubMed
Department of Clinical Chemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Catharina M Korse in
Google Scholar
PubMed
Department of Gastroenterology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Wieke H Verbeek in
Google Scholar
PubMed
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Margot E T Tesselaar in
Google Scholar
PubMed
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by Gerlof D Valk in
Google Scholar
PubMed
with a median of 4 samples per patient (range: 2–12) in an average of 46 months of follow-up (6–71 months). CT was the most common imaging modality used ( n = 533), followed by DOTA-PET/CT ( n = 118) and MRI ( n = 71). During follow-up, 70 patients
Search for other papers by Ruth Percik in
Google Scholar
PubMed
Search for other papers by Sherwin Criseno in
Google Scholar
PubMed
Search for other papers by Safwaan Adam in
Google Scholar
PubMed
Search for other papers by Kate Young in
Google Scholar
PubMed
Royal Marsden Hospital, London, UK
Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed
-stimulating hormone (TSH) and gonadotrophin deficiency ( 12 , 18 , 19 ). We, therefore, propose that hypophysitis should be reserved to describe either the symptomatic phase with headache or MRI findings of enlarged pituitary, whilst ICPI-induced hypopituitarism is
Search for other papers by Hélène Singeisen in
Google Scholar
PubMed
Search for other papers by Mariko Melanie Renzulli in
Google Scholar
PubMed
Search for other papers by Vojtech Pavlicek in
Google Scholar
PubMed
Search for other papers by Pascal Probst in
Google Scholar
PubMed
Search for other papers by Fabian Hauswirth in
Google Scholar
PubMed
Search for other papers by Markus K Muller in
Google Scholar
PubMed
Search for other papers by Magdalene Adamczyk in
Google Scholar
PubMed
Search for other papers by Achim Weber in
Google Scholar
PubMed
Search for other papers by Reto Martin Kaderli in
Google Scholar
PubMed
Search for other papers by Pietro Renzulli in
Google Scholar
PubMed
endocrine tumors in MEN4 and MEN1, respectively. For MEN1, this percentage amounts to 20% for clinically apparent adenomas and up to 40% if adenomas detected by hormonal testing or MRI screening are included ( 3 , 7 , 8 , 14 , 47 ). With regards to MEN4